Canara Robeco Large Cap Fund - Direct (G) vs Nippon India Pharma Fund - Direct (G)

Canara Robeco Large Cap Fund - Direct (G) vs Nippon India Pharma Fund - Direct (G)

stock1

Canara Robeco Large Cap Fund - Direct (G)

-1.29%

stock2

Nippon India Pharma Fund - Direct (G)

7.4%

Loading chart...

About Fund

Deutsche Bank A.G. HDFC Bank Limited. Stock Holding Corporation of India Limited.

Canbank Computer Services Ltd., Bangalore Canbank Investment Management Services Ltd., Mumbai In-house R&T for Cangilt & Cangilt PGS Schemes Computer Age Management Services Pvt. Ltd., Chennai

Deutsche Bank AG

Karvy Computershare Pvt. Ltd.

Very High Risk

100

16692.31

2.25

71.62

January 1, 2013

0

Very High Risk

5000

9044.23

1.12

634.5023

January 1, 2013

1

11.26 %

11.15 %

-1.29 %

14.01 %

19.35 %

7.4 %

Ravi Gopalakrishna

MS (Fin), MBA

Has over 25 years of experience in research and asset management business. During his career, he has worked across many Asset Management Companies, including Canara Robeco AMC, Pramerica AMC, and Sun F&C AMC. He has managed several funds across Large Cap, Multi-cap and Mid cap Strategies. He has a very strong research background and has sound knowledge of the fund management business.

Shridatta Bhandwaldar

BE (Mechanical),MMS (Finance)

Prior to joining Canara Robeco Mutual Fund he was associated with SBI Pension Funds Pvt. Ltd. (Jul 2012-Jun 2016) as Head-Research, Heritage India Advisory Pvt. Ltd. (Oct 2009-Jun 2012) as Senior Equity Analyst, Motilal Oswal Securities (Jan 2008-Sep 2009) and MF Global Securities (Apr 2006-Dec 2008).

Sailesh Raj Bhan

MBA (Finance), CFA.

Mr.Bhan is an MBA with specialization in Finance and CFA. Has over 9 Yrs. of experience in Equity Securities Research & Sequeir Investment Pvt. Ltd. for 5 years and with Emkay Share & stock Broker Pvt. Ltd. for 2 years.

Get your FAQs right